Indications to Switch Therapies for Myelofibrosis Patients

Project Oncology®

Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Justin Arnall, PharmD, BCOP, CPP
Guest: Jerry L. Spivak MD, MACP
While managing patients with myelofibrosis, there are certain indications that it may be time to switch therapies. And working with your patient will help with a timely and seamless transition. To learn more about these best practices, join Dr. Charles Turck as he speaks with Dr. Justin Arnal, Clinical Coordinator of Hematology at Atrium Health Specialty Pharmacy Service in Charlotte, North Carolina, and Dr. Jerry Spivak, Emeritus Professor Medicine at the Johns Hopkins University School of Medicine.